PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31494731-2 2019 Dyskinesia improvement with STN DBS is believed to result entirely from levodopa reduction. Levodopa 72-80 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 28-31 31494731-9 2019 Dyskinesias after STN DBS improved more than predicted by levodopa reduction alone. Levodopa 58-66 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 18-21 26754997-10 2016 STN DBS in patients with motor signs that are less responsive to levodopa results in shorter duration of clinical benefits. Levodopa 65-73 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 0-3 30839077-10 2019 CONCLUSION: Patients with persistent OFFmotor symptoms after STN-DBS should be screened for levodopa-responsiveness, which can serve as a benchmark for best achievable motor benefit. Levodopa 92-100 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 61-64 29422851-3 2017 The patient was treated with bilateral STN DBS after developing side effects related to L-dopa. Levodopa 88-94 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 39-42 26394059-2 2015 Because STN-DBS is effective in patients with PD whose motor symptoms are dramatically alleviated by L-3,4-dihydroxyphenylalanine (L-DOPA) treatment, the higher preoperative catecholamine levels might be related to the better clinical outcome after surgery. Levodopa 101-129 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 8-11 26394059-13 2015 The preoperative plasma levels of L-DOPA had significantly negative correlations with postoperative UPDRS- III score in off phase three months after STN-DBS. Levodopa 34-40 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 149-152 23916724-7 2013 STN-DBS could remarkably reduce levodopa equivalent daily dose at 7 years. Levodopa 32-40 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 0-3 26788349-4 2015 We present a case of inappropriate laughter lacking mirth as a levodopa OFF phenomenon in a patient with PD, whose laughter also worsened with STN-DBS in his non-medicated state. Levodopa 63-71 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 143-146 26788349-6 2015 The case demonstrates pseudobulbar laughter as a levodopa OFF phenomenon that is also exacerbated by STN-DBS. Levodopa 49-57 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 101-104 26558134-10 2015 The impact of levodopa intake on vowel articulation changed with STN DBS: before surgery, levodopa impaired articulation, while it no longer had a negative effect after surgery. Levodopa 14-22 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 65-68 26558134-10 2015 The impact of levodopa intake on vowel articulation changed with STN DBS: before surgery, levodopa impaired articulation, while it no longer had a negative effect after surgery. Levodopa 90-98 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 65-68 26558134-12 2015 These results indicate that while STN DBS could lead to a direct deterioration in articulation, it may indirectly improve it by reducing the levodopa dose required to manage motor symptoms. Levodopa 141-149 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 34-37 25172808-13 2014 The improved motor response to l-DOPA after subthalamotomy in the parkinsonian monkeys investigated may be associated with an increased synthesis and expression of D1 receptors ipsilateral to STN lesion of the direct pathway. Levodopa 31-37 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 192-195 24687897-6 2014 The annual decline in the mini-mental state examination score was 0.4 +- 1.7 with impaired attention and executive function and a higher levodopa equivalent dose at baseline being the predictors of a faster global cognitive decline after STN DBS. Levodopa 137-145 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 238-241 24182523-1 2014 UNLABELLED: Deep brain stimulation of the subthalamic nuclei (STN-DBS) for the treatment of levodopa-induced motor complications in advanced Parkinson"s disease (APD) has been associated with neuropsychiatric disorders. Levodopa 92-100 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 62-65 22121348-5 2011 STN-DBS allowed complete postoperative levodopa withdrawal and HAART restart, without infectious complications after 12 months of follow-up. Levodopa 39-47 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 0-3 23395217-1 2013 BACKGROUND: Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) represents a valid therapeutic option for advanced Parkinson"s disease (PD), leading to a significant amelioration of motor fluctuations and levodopa-induced involuntary movements (IM). Levodopa 206-214 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 56-59 23196528-3 2012 Furthermore, levodopa-induced dyskinesias are dramatically improved because STN stimulation permits an approximately 50% reduction in antiparkinsonian treatment. Levodopa 13-21 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 76-79 22366535-7 2012 l-dopa had no effects on voluntary blinking but reversed the increased inter-phase pause duration seen during STN-DBS. Levodopa 0-6 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 110-113 23095782-5 2012 In comparison to controls, a trend to a slightly worse deterioration in phonemic verbal fluency was observed in the STN-DBS patients and was significantly correlated with reductions in the L-dopa-equivalent daily dose (r = 0.850, p = 0.007). Levodopa 189-195 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 116-119 21316292-1 2011 Subthalamic nucleus deep brain stimulation (STN-DBS) is currently the treatment of choice for medication-resistant levodopa-related motor complications in patients with Parkinson"s disease (PD). Levodopa 115-123 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 44-47 18668617-7 2008 In the few cases of levodopa-induced FOG, STN stimulation can indirectly be effective, thanks to a great decrease or arrest of levodopa. Levodopa 127-135 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 42-45 20824733-1 2010 There is a consensus that in Parkinson"s disease, the extent of preoperative levodopa responsiveness predicts the efficacy of subthalamic nucleus deep brain stimulation (STN DBS). Levodopa 77-85 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 170-173 21992878-12 2010 Levodopa could be prescribed at optimum doses following STN-DBS in patients with YOPD as abnormal movements are better controlled following STN-DBS implantation. Levodopa 0-8 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 56-59 21992878-12 2010 Levodopa could be prescribed at optimum doses following STN-DBS in patients with YOPD as abnormal movements are better controlled following STN-DBS implantation. Levodopa 0-8 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 140-143 20673310-2 2010 High-frequency stimulation of the subthalamic nucleus (STN-HFS) alleviates parkinsonian motor symptoms and indirectly improves dyskinesia by decreasing the L-DOPA requirement. Levodopa 156-162 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 55-58 19556833-6 2009 Preoperative levodopa responsiveness only led to consistent UPDRS part III improvement from STN-DBS at 3 months, and this predictive value did not exist in the long term. Levodopa 13-21 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 92-95 18164541-1 2008 OBJECTIVES: The goal of this study was to assess the effect of bilateral subthalamic deep brain stimulation (STN DBS) on levodopa-induced diphasic dyskinesia in patients with Parkinson disease (PD). Levodopa 121-129 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 109-112 20927559-8 2010 CONCLUSION: Our findings suggest that 123I-MIBG scintigraphy in combination with levodopa-responsiveness evaluation may represent a useful tool for prediction of outcomes in patients subjected to STN stimulation. Levodopa 81-89 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 196-199 18668617-4 2008 STN stimulation was reported to improve levodopa-responsive FOG. Levodopa 40-48 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 0-3 18668617-7 2008 In the few cases of levodopa-induced FOG, STN stimulation can indirectly be effective, thanks to a great decrease or arrest of levodopa. Levodopa 20-28 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 42-45 15390056-2 2004 We present a case of an individual with juvenile parkinsonism caused by homozygous deletion of exon 3 in the parkin gene with disabling long-term side-effects from levodopa who underwent bilateral STN neuromodulation. Levodopa 164-172 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 197-200 17712844-6 2007 The percentage improvement of mFOG and UPDRS motor scores by STN DBS during levodopa off period was calculated. Levodopa 76-84 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 61-64 17712844-8 2007 During levodopa off period, STN DBS improved the UPDRS motor scores by 32.3% and the mFOG scores by 56.6%. Levodopa 7-15 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 28-31 16788774-8 2006 RESULTS: HFS-STN resulted in significant improvement of motor function (62.8%) in off-medication state and levodopa-equivalent dose reduction of 68.7% (p < 0.05). Levodopa 107-115 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 13-16 17443692-4 2007 Levodopa response significantly decreased postoperatively by 31.1% at 3 years and 32.3% at 5 years, possibly related to the reduction in medication requirement, direct STN stimulation effect or PD progression. Levodopa 0-8 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 168-171 17156382-5 2006 These findings show that functional gender-related differences in the central nervous system involve the human subthalamic area (STN) and its response to levodopa in Parkinson"s disease. Levodopa 154-162 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 129-132 16905880-1 2006 We examined the direct effect of deep brain stimulation of the subthalamic nucleus (STN-DBS) on levodopa-induced peak-dose dyskinesia in 45 patients with Parkinson"s disease (PD) without reducing the levodopa dosage during the early period after surgery. Levodopa 96-104 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 84-87 15390056-4 2004 Because levodopa responsiveness is a predictor of STN-DBS efficacy, we argued that this kind of surgical approach might be efficacious in hereditary parkin-linked juvenile parkinsonism. Levodopa 8-16 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 50-53 11835449-1 2002 Bilateral subthalamic nucleus stimulation (STN-DBS) is used to improve parkinsonian symptoms and attenuate levodopa-induced motor complications. Levodopa 107-115 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 43-46 12874410-1 2003 A 59-year-old woman with levodopa-responsive parkinsonism complicated by motor fluctuations and generalized levodopa dyskinesia underwent bilateral subthalamic deep brain stimulation (STN DBS) 7 years after symptom onset. Levodopa 25-33 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 184-187 15249627-0 2004 L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction. Levodopa 0-6 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 44-47 11835462-1 2002 Two cases of postural asymmetries following unilateral stereotaxic subthalamotomy were observed with head and body tilting to the side contralateral to the STN lesion, which corrected itself completely or partially with levodopa treatment. Levodopa 220-228 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 156-159 34750479-1 2021 In Parkinson"s disease (PD), the effects of both Ldopa and subthalamic deep brain stimulation (STN-DBS) are known to change cost-valuation. Levodopa 49-54 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 95-98 33216337-1 2021 AIM: In this study, we planned to investigate the effect of preoperative levodopa responsiveness to clinical outcomes in the first postoperative year and to evaluate the changes in the postoperative levodopa responsiveness in patients undergoing STN DBS. Levodopa 199-207 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 246-249 33216337-10 2021 CONCLUSION: In this study, we confirm that the response of L-dopa decreases after DBS of the STN. Levodopa 59-65 eukaryotic translation elongation factor 1 alpha 2 Homo sapiens 93-96